3SBIO (01530) rose more than 6%, reaching HK$32.58 by the time of writing, with a trading volume of HK$413 million. The surge follows the company's presentation of Phase 2 clinical trial data for its drug 707 in combination with chemotherapy for 1LNSCLC at the 2025 STIC conference.

Additionally, Pfizer announced its global clinical strategy for 707, designating it as a core pipeline asset after entering an agreement with 3SBIO. Pfizer has already submitted five new clinical applications and plans to initiate trials for 10 new indications and over 10 novel combination therapies by late 2026 as part of its second-wave development plan.

Guosen Securities issued a research note highlighting 3SBIO's rapid progress in innovative drug development and its successful major licensing deal, which supports steady earnings growth. The brokerage raised its profit forecast, projecting net profits attributable to shareholders of RMB 9.955 billion, RMB 2.875 billion, and RMB 3.212 billion for 2025–2027, respectively.

With 3SBIO accelerating global clinical development for its core product, Guosen maintains an "Outperform" rating on the stock.